vs

Side-by-side financial comparison of Biglari Holdings Inc. (BH) and CareDx, Inc. (CDNA). Click either name above to swap in a different company.

CareDx, Inc. is the larger business by last-quarter revenue ($117.7M vs $99.9M, roughly 1.2× Biglari Holdings Inc.). CareDx, Inc. runs the higher net margin — 2.4% vs -49.9%, a 52.3% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs 9.6%). Biglari Holdings Inc. produced more free cash flow last quarter ($6.4M vs $514.0K). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs 5.7%).

Biglari Holdings Inc. is an American holding company headquartered in San Antonio, Texas, founded by entrepreneur Sardar Biglari. Its subsidiaries include Steak 'n Shake, Maxim magazine, First Guard Insurance, Southern Pioneer Insurance, Southern Oil, Abraxas Petroleum and Western Sizzlin'.

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

BH vs CDNA — Head-to-Head

Bigger by revenue
CDNA
CDNA
1.2× larger
CDNA
$117.7M
$99.9M
BH
Growing faster (revenue YoY)
CDNA
CDNA
+29.4% gap
CDNA
39.0%
9.6%
BH
Higher net margin
CDNA
CDNA
52.3% more per $
CDNA
2.4%
-49.9%
BH
More free cash flow
BH
BH
$5.9M more FCF
BH
$6.4M
$514.0K
CDNA
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
5.7%
BH

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BH
BH
CDNA
CDNA
Revenue
$99.9M
$117.7M
Net Profit
$-49.9M
$2.8M
Gross Margin
58.3%
Operating Margin
-64.1%
1.0%
Net Margin
-49.9%
2.4%
Revenue YoY
9.6%
39.0%
Net Profit YoY
-385.3%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BH
BH
CDNA
CDNA
Q1 26
$117.7M
Q4 25
$99.9M
$108.4M
Q3 25
$99.7M
$100.1M
Q2 25
$100.6M
$86.7M
Q1 25
$95.0M
$84.7M
Q4 24
$91.1M
$86.6M
Q3 24
$90.4M
$82.9M
Q2 24
$91.1M
$92.3M
Net Profit
BH
BH
CDNA
CDNA
Q1 26
$2.8M
Q4 25
$-49.9M
$-4.1M
Q3 25
$-5.3M
$1.7M
Q2 25
$50.9M
$-8.6M
Q1 25
$-33.3M
$-10.4M
Q4 24
$-10.3M
$87.7M
Q3 24
$32.1M
$-10.6M
Q2 24
$-48.2M
$-4.6M
Gross Margin
BH
BH
CDNA
CDNA
Q1 26
Q4 25
58.3%
Q3 25
58.1%
Q2 25
60.2%
Q1 25
60.3%
Q4 24
60.6%
Q3 24
59.9%
Q2 24
59.5%
Operating Margin
BH
BH
CDNA
CDNA
Q1 26
1.0%
Q4 25
-64.1%
-5.6%
Q3 25
-7.6%
-0.2%
Q2 25
64.7%
-12.8%
Q1 25
-43.3%
-15.8%
Q4 24
-19.7%
97.5%
Q3 24
47.9%
-16.6%
Q2 24
-69.0%
-7.9%
Net Margin
BH
BH
CDNA
CDNA
Q1 26
2.4%
Q4 25
-49.9%
-3.8%
Q3 25
-5.3%
1.7%
Q2 25
50.6%
-9.9%
Q1 25
-35.0%
-12.2%
Q4 24
-11.3%
101.3%
Q3 24
35.5%
-12.8%
Q2 24
-52.9%
-5.0%
EPS (diluted)
BH
BH
CDNA
CDNA
Q1 26
$0.05
Q4 25
$-0.08
Q3 25
$0.03
Q2 25
$-0.16
Q1 25
$-0.19
Q4 24
$1.60
Q3 24
$-0.20
Q2 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BH
BH
CDNA
CDNA
Cash + ST InvestmentsLiquidity on hand
$268.8M
$77.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$523.4M
Total Assets
$1.0B
$411.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BH
BH
CDNA
CDNA
Q1 26
$77.9M
Q4 25
$268.8M
$177.2M
Q3 25
$272.5M
$194.2M
Q2 25
$32.8M
$186.3M
Q1 25
$28.7M
$230.9M
Q4 24
$30.7M
$260.7M
Q3 24
$29.9M
$240.9M
Q2 24
$26.9M
$228.9M
Total Debt
BH
BH
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$0
Stockholders' Equity
BH
BH
CDNA
CDNA
Q1 26
Q4 25
$523.4M
$303.1M
Q3 25
$580.3M
$311.1M
Q2 25
$589.3M
$327.4M
Q1 25
$539.8M
$379.3M
Q4 24
$573.0M
$378.4M
Q3 24
$601.8M
$273.2M
Q2 24
$569.2M
$264.7M
Total Assets
BH
BH
CDNA
CDNA
Q1 26
$411.1M
Q4 25
$1.0B
$413.2M
Q3 25
$1.1B
$432.3M
Q2 25
$863.6M
$444.3M
Q1 25
$829.1M
$489.6M
Q4 24
$866.1M
$491.1M
Q3 24
$865.1M
$477.0M
Q2 24
$809.1M
$466.8M
Debt / Equity
BH
BH
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BH
BH
CDNA
CDNA
Operating Cash FlowLast quarter
$17.8M
$4.3M
Free Cash FlowOCF − Capex
$6.4M
$514.0K
FCF MarginFCF / Revenue
6.4%
0.4%
Capex IntensityCapex / Revenue
11.4%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$76.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BH
BH
CDNA
CDNA
Q1 26
$4.3M
Q4 25
$17.8M
$21.4M
Q3 25
$31.2M
$37.4M
Q2 25
$42.1M
$9.9M
Q1 25
$15.8M
$-26.6M
Q4 24
$18.0M
$21.9M
Q3 24
$10.8M
$12.5M
Q2 24
$1.8M
$18.9M
Free Cash Flow
BH
BH
CDNA
CDNA
Q1 26
$514.0K
Q4 25
$6.4M
Q3 25
$22.3M
Q2 25
$39.4M
Q1 25
$8.5M
Q4 24
$10.9M
Q3 24
$3.7M
Q2 24
$-10.0M
FCF Margin
BH
BH
CDNA
CDNA
Q1 26
0.4%
Q4 25
6.4%
Q3 25
22.4%
Q2 25
39.2%
Q1 25
8.9%
Q4 24
12.0%
Q3 24
4.1%
Q2 24
-11.0%
Capex Intensity
BH
BH
CDNA
CDNA
Q1 26
Q4 25
11.4%
Q3 25
9.0%
Q2 25
2.7%
Q1 25
7.7%
Q4 24
7.8%
Q3 24
7.8%
Q2 24
13.0%
Cash Conversion
BH
BH
CDNA
CDNA
Q1 26
1.54×
Q4 25
Q3 25
22.30×
Q2 25
0.83×
Q1 25
Q4 24
0.25×
Q3 24
0.33×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BH
BH

Products$45.9M46%
Franchisor$20.5M21%
Insurance Operations$19.1M19%
Oil And Gas Segment$5.4M5%
Royalty$4.1M4%
Abraxas Petroleum$2.7M3%
Other$2.2M2%

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

Related Comparisons